The five cardiovascular outcome trials (CVOT) conducted in patients with type 2 diabetes
mellitus so far have shown that renal sodium-glucose cotransporters two inhibitors
(SGLT2i) are cardiovascular (CV) safe [
1
,
2
,
3
,
4
,
5
]. This finding paved the way for their use in patients with type 2, and even type
1, diabetes to reduce the HbA1c by 0.5 to 1.5%, depending on the baseline values.
However, CVOT demonstrated a CV benefits of SGLT2i well beyond their antidiabetic
effect.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med. 2015; 373: 2117-2128
- Dapagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2019; 380: 347-357
- Canagliflozin and cardiovascular and renal events in type 2 diabetes.N Engl J Med. 2017; 377: 644-657
- Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N Engl J Med. 2019; 380: 2295-2306
- Cardiovascular outcomes with ertugliflozin in type 2 diabetes.N Engl J Med. 2020; 383: 1425-1435
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet. 2019; 393: 31-39
- Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.JAMA Cardiol. 2021; 6: 148-158
- Dapagliflozin in patients with heart failure and reduced ejection fraction.N Engl J Med. 2019; 381: 1995-2008
- Cardiovascular and renal outcomes with empagliflozin in heart failure.N Engl J Med. 2020; 383: 1413-1424
- Dapagliflozin in patients with chronic kidney disease.N Engl J Med. 2020; 383: 1436-1446
- Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-reduced trial.Eur Heart J. 2021; 42: 671-680
- Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.Nat Rev Endocrinol. 2020; 16: 556-577
- Effect of SGLT-2 inhibitors on cardiovascular outcomesvin heart failure patients: a meta-analysis of randomized controlled trials.Eur J Intern Med. 2021; ([TO PRODUCTION: PLEASE UPDATE WITH DOI])
- Sotagliflozin in patients with diabetes and recent worsening heart failure.N Engl J Med. 2021; 384: 117-128
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.Eur Heart J. 2020; 41: 255-323
- Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming.Diabetes Care. 2020; 43: 501-507
- Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits.Diabetologia. 2017; 60: 568-573
- Empagliflozin in heart failure: diuretic and cardiorenal effects.Circulation. 2020; 142: 1028-1039
- A role for tubular Na(+)/H(+) exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.Am J Physiol Renal Physiol. 2020; 319: F712-F728
- Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).Eur J Heart Fail. 2020; 22: 713-722
- How should we sequence the treatments for heart failure and a reduced ejection fraction?: A redefinition of evidence-based medicine.Circulation. 2021; 143: 875-877
- Contribution of hematocrit to early mortality after ischemic stroke.Eur Neurol. 2007; 58: 233-238
- SGLT2 inhibitors and amputations in the US FDA adverse event reporting system.Lancet Diabetes Endocrinol. 2017; 5: 680-681
- Use and effectiveness of dapagliflozin in routine clinical practice: an Italian multicentre retrospective study.Diabetes Obes Metab. 2018; 20: 1781-1786
Article info
Publication history
Published online: April 06, 2021
Accepted:
March 19,
2021
Received:
March 7,
2021
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trialsEuropean Journal of Internal MedicineVol. 87
- PreviewHeart failure (HF) is a highly prevalent disease with considerable morbidity and mortality. It is estimated that approximately 50 million people are afflicted with this disease worldwide. The disease burden of HF represents one of the most serious health concerns facing society today (1, 2). Prognosis of HF remains unsatisfactory, and multiple comorbidities with HF impede therapeutic options. Among patients with HF, type 2 diabetes mellitus (T2DM) is a fairly common comorbidity that is present in 20–40% of all patients (3).
- Full-Text
- Preview
